Monoamine oxidase is a flavin enzyme that catalyzes the oxidation of monoamine
neurotransmitters in the brain. Various toxic by-products, aldehydes and hydrogen peroxide …

Well‐developed asymmetric organocatalysis has been widely incorporated in various
cascade/tandem sequences, providing a simple access to structurally complex target …

Monoamine Oxidase B is considered a successful target for developing antiparkinsonian
drugs. Due to the side effects of current MAO-B inhibitors, there's an urgent need for novel …

Monoamine oxidase (MAO) inhibitors have made significant contributions and remain an
indispensable approach of molecular and mechanistic diversity for the discovery of …

This is an overview of the metabolic reactions of drugs, natural products, physiological
compounds, and other (general) chemicals catalyzed by flavin monooxygenase (FMO) …

Monoamine oxidase (MAO) catalyzes the oxidation of monoamines and its two isoforms,
MAO-A and MAO-B, break down neurotransmitter amines. Of the compounds isolated from …

This comprehensive review describes methods for the preparation of 1-indanones published
in original and patent literature from 1926 to 2017. More than 100 synthetic methods utilizing …

Neurodegenerative diseases (NDs) are described as multifactorial and progressive
syndromes with compromised cognitive and behavioral functions. The multi-target-directed …

Naturally occurring flavonoids display a plethora of different biological activities, but
emerging evidence suggests that this class of compounds may also act as antidepressant …

Parkinson's disease is considered the second most frequent neurodegenerative disease. It
is described by the loss of dopaminergic neurons in the mid-brain. For many decades, L …